iShares ESG Aware MSCI USA Value ETF (EVUS)
Live price chart, market sentiment, and community perspectives for iShares ESG Aware MSCI USA Value ETF (CBOE: EVUS).
Live price chart, market sentiment, and community perspectives for iShares ESG Aware MSCI USA Value ETF (CBOE: EVUS).
On our desk, looking at the Q2 2026 institutional filings for EVUS, we noticed a healthy accumulation pattern: 31 funds opened new positions and 68 increased theirs, easily outpacing the 22 reductions and 11 closures. With total assets sitting around $381 million and a low expense ratio of 0.18%, the vehicle remains attractive for institutional portfolios seeking large-cap value with ESG integration. However, portfolio managers need to account for the shift noted in the February 2026 supplement where the fund moved from non-diversified to diversified status, altering how risk concentrations are managed internally.
From a risk analysis standpoint, EVUS presents a fascinating contradiction. While its 5-year and 10-year Morningstar risk scores read 'Low' against the US Fund Large Value category, its short-term metrics reveal some structural friction. The 3-year Sharpe ratio of 0.81 lags both the category median of 0.91 and the MSCI USA Value Extended ESG Focus Index of 1.08. Furthermore, its 3-year downside capture sits at 107, indicating that during recent pullbacks, it absorbed slightly more downside than its peers, culminating in a 3-year worst drawdown of -9.5% versus the category's -8.7%.
When evaluating EVUS for quantitative model integration, analysts must account for the recent regulatory updates from the February 18, 2026 supplement. The removal of 'Non-Diversification Risk' from its summary principal risks and its official migration to the 'Diversified Funds' column in the Statement of Additional Information changes historical baseline assumptions. While the fund trades at a comfortable NAV around $37.03 to $37.36 with a 35% turnover and a modest 1.57% SEC yield, the quantitative focus must shift toward verifying whether its 5-year beta of 0.84 compensates accurately for the recent uptick in downside volatility observed over the trailing 3-year window.
Explore plasma cleansing, somatic organ swaps, and BCI.